Company intelligence / Profile preview

D2M Biotherapeutics

Natick, Massachusetts, United Statesd2mbio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

D2M has initiated a first-in-human Phase 1 trial of DM919, an anti-MICA/B monoclonal antibody, in advanced solid tumors. The study is evaluating safety, tolerability, pharmacokinetics/dynamics, and preliminary efficacy both as monotherapy and in combination with pembrolizumab. Preclinical data suggest synergistic effects with anti-PD1 agents. No published clinical efficacy results yet.

Therapeutic areas: OncologyImmunologyDermatology
Modalities: Monoclonal antibodies (mAbs)Bispecific antibodiesAntibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

1 asset

DM919

Beyond the preview

Go deeper on D2M Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D2M Biotherapeutics.

Explore the full profile